Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing

Vaccine

Volumn 32, Issue 34, 2014, Pages 4267-4274

  Tyler, Mitchell ^a   Tumban, Ebenezer ^a   Dziduszko, Agnieszka ^a   Ozbun, Michelle A ^a   Peabody, David S ^a   Chackerian, Bryce ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

HPV vaccine; L2; Neutralizing epitope; Virus like particles

Indexed keywords

EPITOPE; NEUTRALIZING ANTIBODY; PEPTIDE; WART VIRUS VACCINE; CAPSID PROTEIN; L2 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE;

ANIMAL EXPERIMENT; ARTICLE; BACTERIOPHAGE; CONSENSUS SEQUENCE; CONTROLLED STUDY; CROSS PROTECTION; DRUG MEGADOSE; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS LIKE AGENT; WART VIRUS; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; FEMALE; IMMUNOLOGY; MOLECULAR GENETICS; PAPILLOMAVIRUS INFECTIONS; SERODIAGNOSIS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID PROTEINS; CONSENSUS SEQUENCE; CROSS PROTECTION; EPITOPES; FEMALE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84903816314     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.06.054     Document Type: Article

References (43)

1. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121:621-632.
2. Schiller J.T., Castellsague X., Garland S.M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30(Suppl. 5):F123-F138.
3. Day P.M., Kines R.C., Thompson C.D., Jagu S., Roden R.B., Lowy D.R., et al. In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe 2010, 8:260-270.
4. Richards R.M., Lowy D.R., Schiller J.T., Day P.M. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Nat Acad Sci USA 2006, 103:1522-1527.
5. Christensen N.D., Kreider J.W., Kan N.C., DiAngelo S.L. The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology 1991, 181:572-579.
6. Campo M.S., Grindlay G.J., O'Neil B.W., Chandrachud L.M., McGarvie G.M., Jarrett W.F. Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J Gen Virol 1993, 74(Pt 6):945-953.
7. Lin Y.L., Borenstein L.A., Selvakumar R., Ahmed R., Wettstein F.O. Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology 1992, 187:612-619.
8. Roden R.B., Yutzy WHt, Fallon R., Inglis S., Lowy D.R., Schiller J.T. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 2000, 270:254-257.
9. Rubio I., Seitz H., Canali E., Sehr P., Bolchi A., Tommasino M., et al. The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies. Virology 2011, 409:348-359.
10. Gambhira R., Karanam B., Jagu S., Roberts J.N., Buck C.B., Bossis I., et al. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol 2007, 81:13927-13931.
11. Schellenbacher C., Roden R., Kirnbauer R. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J Virol 2009, 83:10085-10095.
12. Kondo K., Ishii Y., Ochi H., Matsumoto T., Yoshikawa H., Kanda T. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology 2007, 358:266-272.
13. Karanam B., Jagu S., Huh W.K., Roden R.B. Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol 2009, 87:287-299.
14. Chackerian B. Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines 2007, 6:381-390.
15. Schodel F., Wirtz R., Peterson D., Hughes J., Warren R., Sadoff J., et al. Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes. J Exp Med 1994, 180:1037-1046.
16. Jegerlehner A., Tissot A., Lechner F., Sebbel P., Erdmann I., Kundig T., et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 2002, 20:3104-3112.
17. Chackerian B., Rangel M., Hunter Z., Peabody D.S. Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses. Vaccine 2006, 24:6321-6331.
18. Peabody D.S., Manifold-Wheeler B., Medford A., Jordan S.K., do Carmo Caldeira J., Chackerian B. Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2. J Mol Biol 2008, 380:252-263.
19. Jagu S., Karanam B., Gambhira R., Chivukula S.V., Chaganti R.J., Lowy D.R., et al. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Nat Cancer Inst 2009, 101:782-792.
20. Nieto K., Weghofer M., Sehr P., Ritter M., Sedlmeier S., Karanam B., et al. Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate. PLoS One 2012, 7:e39741.
21. Varsani A., Williamson A.L., de Villiers D., Becker I., Christensen N.D., Rybicki E.P. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. J Virol 2003, 77:8386-8393.
22. Smith M.L., Lindbo J.A., Dillard-Telm S., Brosio P.M., Lasnik A.B., McCormick A.A., et al. Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications. Virology 2006, 348:475-488.
23. Caldeira Jdo C., Medford A., Kines R.C., Lino C.A., Schiller J.T., Chackerian B., et al. Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. Vaccine 2010, 28:4384-4393.
24. Tumban E., Peabody J., Peabody D.S., Chackerian B. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS One 2011, 6:e23310.
25. Tumban E., Peabody J., Peabody D.S., Chackerian B. A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants. Vaccine 2013, 31:4647-4654.
26. Buck C.B., Pastrana D.V., Lowy D.R., Schiller J.T. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med 2005, 119:445-462.
27. Roberts J.N., Buck C.B., Thompson C.D., Kines R., Bernardo M., Choyke P.L., et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 2007, 13:857-861.
28. Larkin M.A., Blackshields G., Brown N.P., Chenna R., McGettigan P.A., McWilliam H., et al. Clustal W and Clustal X version 2.0. Bioinformatics 2007, 23:2947-2948.
29. Waterhouse A.M., Procter J.B., Martin D.M., Clamp M., Barton G.J. Jalview Version 2-a multiple sequence alignment editor and analysis workbench. Bioinformatics 2009, 25:1189-1191.
30. Day P.M., Pang Y.Y., Kines R.C., Thompson C.D., Lowy D.R., Schiller J.T. A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Clin Vaccine Immunol 2012, 19:1075-1082.
31. Schellenbacher C., Kwak K., Fink D., Shafti-Keramat S., Huber B., Jindra C., et al. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses. J Invest Dermatol 2013, 133:2706-2713.
32. Alphs H.H., Gambhira R., Karanam B., Roberts J.N., Jagu S., Schiller J.T., et al. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Nat Acad Sci USA 2008, 105:5850-5855.
33. Rubio I., Bolchi A., Moretto N., Canali E., Gissmann L., Tommasino M., et al. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20-38) peptide displayed on bacterial thioredoxin. Vaccine 2009, 27:1949-1956.
34. Hunter Z., Smyth H.D., Durfee P., Chackerian B. Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine. Vaccine 2009, 28:403-414.
35. Kawana K., Yoshikawa H., Taketani Y., Yoshiike K., Kanda T. Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J Virol 1999, 73:6188-6190.
36. Slupetzky K., Gambhira R., Culp T.D., Shafti-Keramat S., Schellenbacher C., Christensen N.D., et al. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine 2007, 25:2001-2010.
37. Pineo C.B., Hitzeroth I.I., Rybicki E.P. Immunogenic assessment of plant-produced human papillomavirus type 16 L1/L2 chimaeras. Plant Biotechnol J 2013, 11:964-975.
38. Parra G.I., Bok K., Taylor R., Haynes J.R., Sosnovtsev S.V., Richardson C., et al. Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations. Vaccine 2012, 30:3580-3586.
39. Gao F., Weaver E.A., Lu Z., Li Y., Liao H.X., Ma B., et al. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol 2005, 79:1154-1163.
40. Zhang M., Zhang L., Zhang C., Hong K., Shao Y., Huang Z., et al. DNA prime-protein boost using subtype consensus Env was effective in eliciting neutralizing antibody responses against subtype BC HIV-1 viruses circulating in China. Hum Vaccines Immunother 2012, 8:1630-1637.
41. McBurney S.P., Ross T.M. Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines. Vaccine 2009, 27:4337-4349.
42. Pastrana D.V., Gambhira R., Buck C.B., Pang Y.Y., Thompson C.D., Culp T.D., et al. Cross-neutralization of cutaneous and mucosal papillomavirus types with anti-sera to the amino terminus of L2. Virology 2005, 337:365-372.
43. Tumban E., Peabody J., Tyler M., Peabody D.S., Chackerian B. VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus. PLoS One 2012, 7:e49751.